GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » EBIT per Share

China National Accord Medicines (SZSE:000028) EBIT per Share : ¥4.83 (TTM As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines EBIT per Share?

China National Accord Medicines's EBIT per Share for the three months ended in Mar. 2024 was ¥1.09. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥4.83.

During the past 12 months, the average EBIT per Share Growth Rate of China National Accord Medicines was -4.20% per year. During the past 3 years, the average EBIT per Share Growth Rate was 7.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 11.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was 8.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for China National Accord Medicines's EBIT per Share or its related term are showing as below:

SZSE:000028' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -43.4   Med: 13.9   Max: 201.5
Current: 7.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of China National Accord Medicines was 201.50% per year. The lowest was -43.40% per year. And the median was 13.90% per year.

SZSE:000028's 3-Year EBIT Growth Rate is ranked better than
50.62% of 81 companies
in the Medical Distribution industry
Industry Median: 6.9 vs SZSE:000028: 7.30

China National Accord Medicines's EBIT for the three months ended in Mar. 2024 was ¥605 Mil.


China National Accord Medicines EBIT per Share Historical Data

The historical data trend for China National Accord Medicines's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines EBIT per Share Chart

China National Accord Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.81 4.33 4.06 4.62 4.88

China National Accord Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.14 1.37 1.09 1.28 1.09

China National Accord Medicines EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

China National Accord Medicines's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=2721.608/557.232
=4.88

China National Accord Medicines's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

EBIT per Share(Q: Mar. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=604.996/555.387
=1.09

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines  (SZSE:000028) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


China National Accord Medicines EBIT per Share Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines